A randomized, double-blinded, placebo-controlled phase III trial of HX008 plus irinotecan as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma
单位：[1]Department of Medical Oncology, National Cancer Center/National Clinical ResearchCenter for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and PekingUnion Medical College, Beijing, China[2]Department of Medical Oncology, HenanCancer Hospital, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou,China河南省肿瘤医院[3]Department of Medical Oncology, General Hospital of Ningxia Medical University,Ningxia, China[4]Department of Medical Oncology, Anhui Provincial Hospital,Hefei, China[5]Oncology Department, The Second Affiliated Hospital of SoochowUniversity, Suzhou, China苏州大学附属第二医院[6]Department of Medical Oncology, Shandong Cancer Hospital,Jinan, China[7]Oncology Department, Changzhou Cancer Hospital, Changzhou,China[8]Department of Medical Oncology, Liaoning Cancer Hospital & Institute, Shenyang,China[9]Oncology Department, The First Affiliated Hospital of ZhengzhouUniversity, Zhengzhou, China[10]Department of Medical Oncology, Gansu Wuwei TumorHospital,Wuwei, China[11]Oncology Department, Fujian Cancer Hospital, Xiamen,Fujian, China[12]Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou,China浙江省肿瘤医院[13]Department of Medical Oncology, The Second Hospital of AnhuiMedical University, Hefei, China[14]Department of Medical Oncology, The FourthHospital of Hebei Medical University, Shijiazhuang, China[15]Department of MedicalOncology, The Affiliated Hospital of Qingdao University, Qingdao, China[16]OncologyDepartment, Beijing Friendship Hospital, Capital Medical University, Beijing, China首都医科大学附属北京友谊医院[17]Department of Medical Oncology, Peking Union Medical College Hospital, Beijing,China[18]Oncology Department, Nanjing Drum Tower Hospital, Nanjing, China[19]Oncology Department, Yangzhou First People’s Hospital, Yangzhou, China[20]Department of Medical Oncology, Henan Provincial People’s Hospital, Zhengzhou,China
第一作者单位：[1]Department of Medical Oncology, National Cancer Center/National Clinical ResearchCenter for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and PekingUnion Medical College, Beijing, China
推荐引用方式(GB/T 7714)：
Huang J.,Luo S.,Chen P.,et al.A randomized, double-blinded, placebo-controlled phase III trial of HX008 plus irinotecan as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma[J].ANNALS of ONCOLOGY.2021,32:S1075-S1075.doi:10.1016/j.annonc.2021.08.1548.
APA：
Huang, J.,Luo, S.,Chen, P.,Pan, Y.,Zhuang, Z....&Cang, S..(2021).A randomized, double-blinded, placebo-controlled phase III trial of HX008 plus irinotecan as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma.ANNALS of ONCOLOGY,32,
MLA：
Huang, J.,et al."A randomized, double-blinded, placebo-controlled phase III trial of HX008 plus irinotecan as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma".ANNALS of ONCOLOGY 32.(2021):S1075-S1075
医学